ISPO

Prostate

Analysis of genetic alterations in human prostate cancer

M Watanabe, T Shiraishi, M Murata, K Fukutome, J Kawamura, R Yatani

Beta-microseminoprotein expression in prostate cancer: in situ hybridization and immunohistochemical studies

H Sakai MD, T Tsurusaki MD, T Koji PhD, H Kanetake MD, Y Saito MD, PK Nakane PhD

Alternative transcripts of PSP94 (prostate secretory protein of 94 amino acids) in prostate tissue

JW Xuan PhD, D Wu, S Guo, JL Chin MD

Analysis of the epitope structure recognized by 15 monoclonal antibodies against human PSP94 (prostate secretory protein of 94 amino acids)

JW Xuan PhD, D Wu, S Guo, GL Wright Jr PhD, JL Chin MD

Detection of human papillomavirus DNA in prostate biopsies by using in situ hybridization and hybrid capture system

AI Guney MD PhD, C Mougin MD PhD, S Coumes Marquet PhD, U Ince MD, B Cirakoglu PhD, M Lab MD

Subcellular localization of distinct p53 subentities: a study on human prostate- and bladder cancer cell lines

J Benninghoff, H Selter, B Wullich, G Unteregger, T Zwergel, M Montenarh

The apurinic endonuclease (Ape/ref-i) dna repair enzyme is elevated in pre-malignant and malignant cervical and prostate cancer

MR Kelley PhD, Y Xu PhD, J Broshears PhD, DH Moore MD

Cytoskeletal actin as a intermediate end point marker for bladder cancer management

J Rao MD, G Hemstreet MD PhD

PSA and PS2 expression in prostatic tissue

JM Marechal, Y Lasne, R Dante, M Dawahra, C Prost, JM Dubernard

Examination of prostate-specific antigen (PSA) as a predictive marker for survival in hormone-refractory prostate cancer (HRPC) patients treated with suramin therapy

R Sridhara PhD, M Eisenberger MD, V Sinibaldi RN, L Reyno MD, M Egorin MD

Prostate-specific antigen(PSA) expression and gleason grade; in situ hybridization and immunohistochemical studies of the bioptic prostate cancer specimens

T Tsurusaki MD, T Koji PhD, H Sakai MD, H Kanetake MD, Y Saito MD, PK Nakane PhD

Pre-operative PSA and biopsy grade are poor predictors of microscopic prostate cancer lymph node metastases

G Davis MD, L Bernstein MD, A Schofield LPN, H Zuckerman MD

Can the ratio free PSA/ total psa in the 2.5-10 ng/ml range predict prostatic cancer?

E Lechevallier MD, C Eghazarian MD, JC Ortega MD, D Bretheau MD, C Coulange MD

Estrogen induces apoptosis in a rat pro static adenocarcinoma: association with an increased expression of TGF-beta1 and its type I and type II receptors

K Funa, M Landstrom, S Eklov, P Colosetti, S Nilsson, JE Damber, A Bergh

Androgen blockade prior to radical prostatectomy: can response be predicted?

M Rubenstein PhD, R Sharifi MD, V Ray MD, G Lievano MD, Y Mirochnik, M Shaw MS, P Guinan MD

Significance of trisomy 7 (evaluated by in situ hybridization) in prostatic cancer

L Matturri MD, A Cazzullo ScD, AM Lavezzi MD, R Timossi ScD, R Turconi ScD, F Radice MD

Radical prostatectomy after androgen blockade: are marker and morphologic changes significant?

M Rubenstein PhD, R Sharifi MD, V Ray MD, G Lievano MD, Y Mirochnik, M Shaw MS, P Guinan MD

Palliation of painful osseous metastases by intravenous strontium-89

D Preston MD, M Schiefelbein CNMT, K Baxter MD, M Redick MD PhD, R Robinson MD